AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Piper Sandler Initiates UroGen Pharma Coverage at Overweight with PT $36
ByAinvest
Tuesday, Aug 19, 2025 8:18 am ET1min read
Piper Sandler Initiates UroGen Pharma Coverage at Overweight with PT $36
Piper Sandler has initiated coverage on UroGen Pharma Ltd. with an overweight rating and a price target of $36. The biopharmaceutical company is based in Israel and specializes in developing solutions for cancers and urologic diseases. UroGen has developed RTGel™, a proprietary sustained release, hydrogel-based platform technology that enhances the therapeutic profiles of existing drugs.The company's lead product candidates, MitoGel and VesiGel, are formulated using the RTGel technology. MitoGel (UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma. VesiGel (UGN-102) is a sustained release formulation of high-dose Mitomycin C for the treatment of low-grade non-muscle invasive bladder cancer (LG-NMIBC).
Piper Sandler's analysis suggests that UroGen Pharma's pipeline and technology have significant potential in the market. The firm believes that the company's innovative approach to drug delivery could lead to improved patient outcomes and increased market share.
References:
[1] https://www.marketscreener.com/news/piper-sandler-initiates-urogen-pharma-at-overweight-with-36-price-target-ce7c51ddd981f421
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet